George Budwell

George Budwell


George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next generation vaccines, and cell therapies.

Recent articles

3 Top Healthcare Stocks to Buy in February

Canopy Growth Corporation, MyoKardia, and Blueprint Medicines are all outstanding healthcare picks this month.

3 Top Biotech Stocks to Buy in February

Here's why Viking Therapeutics, Cambrex, and Sarepta Therapeutics are all solid biotech plays this month.

Is Gilead Sciences a Bad News Buy?

Gilead's fourth-quarter numbers failed to hit the mark, but the company firmly believes that better days are directly ahead.